Clinical Trial Update: To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial evaluating the safety and efficacy of TQB2618 injection in combination with Penpulimab for relapsed/refractory lymphoma is underwa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Penpulimab
• TQB2618

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Relapsed/Refractory Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN